Dupilumab May Help in Tough-to-Treat Chronic Spontaneous Urticaria
PHOENIX — Patients who received add-on dupilumab (Dupixent) treatment for chronic spontaneous urticaria (CSU) had reduced symptoms and experienced less itchiness, a phase III trial found. In the 6-month study, participants (adults, adolescents, and children) treated with dupilumab on top of their usual H1-antihistamine (H1-AH) experienced a 4.2-point greater mean reduction in their Itch Severity […]